Evidence map›Paper›PMID 42443628›Full record

ArticleNature chemistry2026

Oxetane-to-azetidine skeletal editing.

Dayu Tian, Like Luo, Xian Xiao, Guang Chen, Liqiang Zhang, Jiaxin Wang, Xiaocheng Wang, Hai-Jun Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dayu Tian *State Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.
Like Luo *State Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.
Xian XiaoState Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.
Guang ChenState Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.
Liqiang ZhangState Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.
Jiaxin WangState Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.
Xiaocheng WangState Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0000-0002-5268-1050
Hai-Jun ZhangState Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China. haijunzhang@ustc.edu.cn.ORCID http://orcid.org/0000-0002-2963-0378

Funding

National Natural Science Foundation of China (National Science Foundation of China) GG2060007012University of Science and Technology of China (USTC) KY2060000237University of Science and Technology of China (USTC) KY2060000253
6 · The paper itself

Abstract

The identity of heteroatoms within bioactive molecules can profoundly influence their physicochemical and biological properties. Evaluating heterocycle analogues featuring distinct heteroatoms for new therapeutic opportunities, however, often requires laborious de novo syntheses. Here we report a straightforward, two-step, one-pot strategy for the direct skeletal editing of readily available oxetanes into azetidines using a broad range of aromatic and aliphatic amines. This transformation proceeds under simple conditions through Lewis acid-mediated intermolecular aminolysis of oxetanes, followed by an intramolecular Mitsunobu-type dehydrative cyclization to forge the azetidine ring. The resulting non-redox skeletal editing platform features broad substrate scope, excellent functional group tolerance and compatibility with complex, drug-like molecules, enabling rapid access to azetidine analogues from oxetane precursors for heterocycle editing in drug discovery.

Indexed as

AzetidinesEthers, CyclicCyclizationazetidineAzetidinesEthers, Cyclicoxetane

Identifiers

PMID42443628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.